Here’s a groundbreaking revelation that could change the lives of countless women: Hormone therapy, long feared to increase breast cancer risk in BRCA carriers, might actually be safer than we thought—and in some cases, even protective. For women with BRCA mutations, the decision to undergo oophorectomy to prevent ovarian cancer often comes with a daunting trade-off: early menopause and its debilitating symptoms. Hot flashes, night sweats, and urogenital discomfort can severely impact quality of life, yet concerns about hormone therapy’s link to breast cancer have left many women and their doctors hesitant to act. But here’s where it gets controversial: a new study presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) suggests that hormone therapy may not elevate breast cancer risk—and in some cases, it might even lower it.
The Study That’s Turning Heads
In a prospective analysis involving 676 pairs of BRCA carriers, researchers found that women who used hormone therapy after surgical menopause did not face a higher breast cancer risk over 5 years compared to those who avoided it. Even more surprising? Among women who underwent hysterectomy and used estrogen-only therapy, breast cancer risk was significantly reduced—by a staggering 63%. This finding aligns with the Women’s Health Initiative, which also observed a protective effect of estrogen-only therapy in the general population. But this is the part most people miss: the study also hints that the combination of estrogen and bazedoxifene, a selective estrogen receptor modulator, might offer a breast cancer-free follow-up period, though more research is needed to confirm this.
Why This Matters—and Why It’s Controversial
For women with BRCA mutations, surgical menopause isn’t just about hot flashes; it’s also linked to long-term risks like cardiovascular disease and osteoporosis. Hormone therapy could be a lifeline, but its association with breast cancer in the general population—particularly when estrogen and progestin are combined—has cast a long shadow. Dr. Joanne Kotsopoulos, the study’s lead investigator, emphasizes that the data now suggest it’s safe to use hormone therapy in this population, at least until around age 50. But here’s the kicker: the study’s relatively short follow-up period and the possibility that hormone users were healthier to begin with leave room for debate. Is the lack of increased risk in combination therapy a fluke, or is there something unique about BRCA carriers that changes the equation? That’s a question researchers are eager to explore.
The Bigger Picture
Guidelines currently recommend oophorectomy by age 40 for BRCA1 carriers and 45 for BRCA2 carriers, leaving many women facing menopause decades earlier than expected. Hormone therapy could alleviate their symptoms, but until now, the fear of breast cancer has often outweighed the benefits. Dr. Virginia Kaklamani points out that this study provides much-needed reassurance, but it also raises a thought-provoking question: Are we underestimating the safety of hormone therapy in this specific population? And if so, how might that change clinical practice?
What’s Next?
While the findings are promising, they’re not the final word. Longer-term studies are needed to fully understand the risks and benefits of hormone therapy in BRCA carriers. In the meantime, the study invites a crucial conversation: Should we reconsider how we approach menopause management in this high-risk group? And what does this mean for the millions of women grappling with these decisions today?
Your Turn: What Do You Think?
Is this study a game-changer, or is it too early to celebrate? Do you think hormone therapy should be more widely recommended for BRCA carriers, or are the risks still too uncertain? Share your thoughts in the comments—this is one conversation that’s just getting started.
